FINNENCE ▪ THE WIRE FILE
THE WIRE · № 77935
News■ Mixed
Steris inks $2.1B Xodus buyout to expand consumables portfolio
KINDNews
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Steris buying Xodus expands consumables but adds integration and leverage risk.
Steris expands consumables via $2.1B buyout
CATALYST TO WATCH
Deal close and synergy guidance
MAIN RISK
Overpaying or integration missteps
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.